ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Profund Advisors LLC

Profund Advisors LLC boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 443.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,656 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,489 shares during the quarter. Profund Advisors LLC owned about 0.10% of ANI Pharmaceuticals worth $1,646,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ANIP. The Manufacturers Life Insurance Company boosted its holdings in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 143 shares during the last quarter. James Investment Research Inc. increased its stake in shares of ANI Pharmaceuticals by 4.3% in the 3rd quarter. James Investment Research Inc. now owns 4,850 shares of the specialty pharmaceutical company’s stock valued at $352,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of ANI Pharmaceuticals by 13.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 211 shares during the last quarter. Versant Capital Management Inc increased its stake in shares of ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 217 shares during the last quarter. Finally, Yousif Capital Management LLC raised its position in shares of ANI Pharmaceuticals by 5.6% in the 3rd quarter. Yousif Capital Management LLC now owns 5,187 shares of the specialty pharmaceutical company’s stock valued at $377,000 after acquiring an additional 275 shares during the period. Institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Jeanne Thoma sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the sale, the director directly owned 26,762 shares in the company, valued at approximately $1,914,285.86. This trade represents a 3.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the completion of the transaction, the chief executive officer directly owned 333,689 shares in the company, valued at approximately $23,988,902.21. The trade was a 1.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 30,412 shares of company stock valued at $2,220,970. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.8%

NASDAQ:ANIP opened at $70.67 on Tuesday. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $95.57. The stock has a 50-day moving average price of $72.86 and a two-hundred day moving average price of $77.62. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 2.31 and a beta of 0.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent analyst reports. Guggenheim reduced their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price for the company. Finally, Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $99.60.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.